<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id>
      <journal-title-group>
        <journal-title>Annals of Hematology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-5555</issn>
      <issn pub-type="epub">1432-0584</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22760926</article-id>
      <article-id pub-id-type="pmc">3494868</article-id>
      <article-id pub-id-type="publisher-id">1511</article-id>
      <article-id pub-id-type="doi">10.1007/s00277-012-1511-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is <italic>eculizumab</italic> indicated?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bellido</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van der Velden</surname>
            <given-names>V. H. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leebeek</surname>
            <given-names>F. W. G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>te Boekhorst</surname>
            <given-names>P. A. W.</given-names>
          </name>
          <address>
            <phone>+31-10-7033123</phone>
            <fax>+31-10-7035814</fax>
            <email>p.teboekhorst@erasmusmc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Hematology, Erasmus Medical Center, Rotterdam, P.O. Box: 2040, 3000 DR Rotterdam, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Department of Immunology, Erasmus Medical Center, Rotterdam, P.O. Box: 2040, 3000 DR Rotterdam, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>7</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>4</day>
        <month>7</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <volume>91</volume>
      <issue>12</issue>
      <fpage>1969</fpage>
      <lpage>1970</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>6</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2012</copyright-statement>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2012</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>We would like to discuss the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by presenting the fatal outcome of one of our patients with this disease. A 30-year-old Caucasian man with a history of auto-immune hepatitis developed pancytopenia. He had no complaints and did not take any medication. On physical examination, a pale man was seen without any other remarkable findings. His hemoglobin was 8.3&#xA0;g/dL (13.8&#x2013;16.9&#xA0;g/dL), leucocytes 0.30 (neutrophils 0.2)&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L (3.5&#x2013;10&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L), platelet count 16&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L (150&#x2013;350&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L) and reticulocytes 8.4&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L (30&#x2013;95&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L) without signs of hemolysis. Bone-marrow biopsy showed reduced cellularity (10&#xA0;%) without any other (including cytogenetic) abnormalities. In peripheral blood, glycosylphosphatidylinositol (PI)-deficient clones were detected in 34, 27, and 1&#xA0;% of the granulocyte, monocyte, and erythroid lineages, respectively. Severe aplastic anemia (SAA) was diagnosed secondary to PNH. Lacking an HLA-identical family donor, standard treatment with immunosuppression was started: rabbit anti-thymocyte globuline, methylprednisolone, and cyclosporine. This resulted in a partial response 3&#xA0;months later: persistent transfusion-dependent anemia without signs of intravascular hemolysis, thrombocytopenia, and a normal leucocyte count. An expansion of the PI-deficient clones up to 86, 86, and 7&#xA0;% of the granulocyte, monocyte, and erythroid lineages, respectively (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) was noted.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>PNH clones at diagnosis (<bold>a</bold>) and their expansion (<bold>b</bold>) after treatment for SAA. Comparison of the PI-deficient clones at diagnosis of severe aplastic anemia (<bold>a</bold>) and after triple immunosuppression (<bold>b</bold>). Monocytes and granulocytes were gated based on scatter characteristics and expression of CD33 and CD45. PI deficiency was analyzed by FLAER and CD14 (monocytes, <italic>left panel</italic>) or FLAER and CD24 (granulocytes, <italic>middle panel</italic>). Erythrocytes (<italic>right panel</italic>) were gated based on scatter characteristics and PI deficiency was analyzed by CD59 and CD55. The <italic>numbers</italic> indicate the percentage of PI-deficient cells (type III completely lacking GPI-linked proteins) within the particular lineage. Minor populations of type II cells (partial lacking GPI-linked proteins) are present as well</p></caption><graphic xlink:href="277_2012_1511_Fig1_HTML" id="MO1"/></fig></p>
    <p>Three months after initial presentation, he was re-admitted to hospital because of abdominal pain and bloody stools. Thrombosis of the superior mesenteric vein was diagnosed and anticoagulant therapy was instituted with nadroparin 15,200&#xA0;IU/day subcutaneously. Eculizumab treatment was considered, but because of the complete absence of intravascular hemolysis, the effect of the anticoagulant therapy was awaited. Subsequently, he developed headache and a left hemiparesis. Repeated CT scans of the brain showed expanding ischemic areas parieto-occipital with secondary bleeding, and the patient finally died.</p>
    <p>Thrombosis is the most feared and life-threatening complication in PNH patients, because after onset, it is frequently progressive and refractory to anticoagulant therapy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The mechanism of thrombotic complications in PNH is not completely understood, but it has mainly been attributed to intravascular hemolysis [<xref ref-type="bibr" rid="CR1">1</xref>]. Experimental studies show that the free plasma hemoglobin liberated during hemolysis scavenges nitric oxide (NO). As a result, NO depletion produces dystonia and spasm of the smooth muscle, suppresses the anti-inflammatory effect on the endothelium and promotes platelet activation and thrombosis [<xref ref-type="bibr" rid="CR3">3</xref>]. Eculizumab is a monoclonal antibody that binds complement factor C5, thereby inhibiting complement activation on erythrocytes and reducing hemolysis. As a result, eculizumab decreases thrombotic risks in PNH patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Interestingly, our patient suffered from progressive abdominal and cerebral thrombotic complications without any signs of intravascular hemolysis. It is also possible that the pathogenesis of thrombosis in PNH might be caused by other mechanisms associated to complement activation and not directly related to hemolysis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. We speculate that the mechanism of thrombosis could be associated to platelet activation caused by the absence of CD59 and CD55 on the platelet surface [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
    <p>Internationally accepted indications for eculizumab treatment include transfusion-dependent hemolysis (four or more transfusions in 12&#xA0;months) and PNH-related complications (i.e., thrombosis or renal failure) regardless of transfusion history [<xref ref-type="bibr" rid="CR3">3</xref>]. Although no clinical data are available, eculizumab could be indicated in patients with thrombotic events in the absence of hemolysis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
  </body>
  <back>
    <ack>
      <sec id="d29e328">
        <title>Open Access</title>
        <p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bijnen</surname>
              <given-names>STA</given-names>
            </name>
            <name>
              <surname>Heerde</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Muus</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mechanism and clinical implications of thrombosis in paroxysmal nocuternal hemoglobinuria</article-title>
          <source>J Thrombo Haemost</source>
          <year>2012</year>
          <volume>10</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04562.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hillmen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Muus</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>D&#xFC;hrsen</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of the complement inhibitor eculizumab on thromboembolism in patient with paroxysmal nocturnal hemoglobinuria</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <fpage>4123</fpage>
          <lpage>4128</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2007-06-095646</pub-id>
          <pub-id pub-id-type="pmid">17702897</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rother</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hillmen</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease</article-title>
          <source>JAMA</source>
          <year>2005</year>
          <volume>293</volume>
          <fpage>1653</fpage>
          <lpage>1662</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.293.13.1653</pub-id>
          <pub-id pub-id-type="pmid">15811985</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>LM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>117</volume>
          <fpage>6786</fpage>
          <lpage>6792</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-02-333997</pub-id>
          <pub-id pub-id-type="pmid">21460245</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luzzatto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gianfaldoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Notaro</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Management of paroxysmal nocturnal haemoglobinuria: a personal view</article-title>
          <source>Br J Haematol</source>
          <year>2011</year>
          <volume>153</volume>
          <fpage>709</fpage>
          <lpage>720</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08690.x</pub-id>
          <pub-id pub-id-type="pmid">21517820</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiedmer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>TL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria</article-title>
          <source>Blood</source>
          <year>1993</year>
          <volume>82</volume>
          <fpage>1192</fpage>
          <lpage>1196</lpage>
          <pub-id pub-id-type="pmid">7688991</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schafer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wiesmann</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Neubauer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eigenthaler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bauersachs</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Channon</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Rapid regulation of platelet activation in vivo by nitric oxide</article-title>
          <source>Circulation</source>
          <year>2004</year>
          <volume>109</volume>
          <issue>15</issue>
          <fpage>1819</fpage>
          <lpage>1822</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.0000126837.88743.DD</pub-id>
          <pub-id pub-id-type="pmid">15066953</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sims</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rollins</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Wiedmer</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex</article-title>
          <source>J Biol Chem</source>
          <year>1989</year>
          <volume>264</volume>
          <fpage>19228</fpage>
          <lpage>19235</lpage>
          <pub-id pub-id-type="pmid">2808422</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brodsky</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>How</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>treat paroxysmal nocturnal hemoglobinuria</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>6522</fpage>
          <lpage>6527</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-03-195966</pub-id>
          <pub-id pub-id-type="pmid">19372253</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Malet</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Rutherford</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Paroxysmal nocturnal hemoglobinuria with no evidence of hemolysis presenting as Budd-Chiari syndrome</article-title>
          <source>Dig Dis Sci</source>
          <year>2000</year>
          <volume>45</volume>
          <fpage>2238</fpage>
          <lpage>2239</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1026467219850</pub-id>
          <pub-id pub-id-type="pmid">11215746</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
